Affimed Therapeutics, a Germany-based biopharmaceutical company developing antibody formats for the treatment of cancer, has closed its series D round of financing at €15.5m ($20m) from a consortium led by Denmark-based peer Novo Nordisk.
Alongside Novo Nordisk in the D round were Aeris Capital, the venture capital firm formed by Klaus Tschira, a co-founder of software conglomerate SAP, and venture capital firms BioMedInvest, LSP Life Sciences Partners and Orbimed.
Affimed will use the new funds to trial its two new drugs. Affimed closed a C round of €20m in 2010. The company raised €30m in a B round in 2007/2008.